5 Years Younger? UthPeak® NMNH Clinical Trial Results Explained

UthPeak®’s Clinical Breakthrough: The World’s Largest NMNH (reduced NMN) Trial

UthPeak® has set a new benchmark in longevity science with the world’s first, largest, and longest human clinical trial on NMNH (reduced NMN). This 90-day, double-blind, placebo-controlled study involved 80 healthy participants, rigorously assessing safety, efficacy, and overall well-being. Following the success of clinically proven UTHEVER® NMN, UthPeak® reaffirms its commitment to clinically proven anti-aging innovations.

Rigorous Science, Trusted Results

• Study Design: A prospective, multi-center, double-blind, placebo-controlled, randomized, multiple-arm, parallel study
• Focus Areas: Safety, NAD+ levels, biological age reversal, energy, and emotional well-being.
• Self-GRAS Confirmation: An independent expert panel confirmed NMNH(Reduced NMN)’s safety for commercial use under FDA safety standards.

Key Findings: Safety, Rejuvenation, and Energy

Safety Confirmed

• No Adverse Effects: The 90-day trial showed no impact on clinical laboratory tests, including blood chemistry, lipid profile, liver function, renal function, and urinalysis.
• Industry Benchmark: UthPeak®NMNH’s (Reduced NMN) Self-GRAS (Generally Recognized As Safe) certification underscores its safety and quality, meeting federal regulations for reasonable certainty of no harm.

Turn Back the Clock: 5 Years Younger

• Biological age, measured by blood biomarkers, decreased by up to 5 years in the NMNH (Reduced NMN). The biological age of the placebo group increased during the trial.
• Biological age, which reflects aging at the cellular level, is a stronger predictor of longevity than chronological age.

3x NAD+ Boost & 35% Energy Surge

• NAD+ Levels: Plasma NAD+ tripled in the NMNH(Reduced NMN) group, while placebo levels remained stagnant.
• Energy & Vitality: Participants reported a 35% increase in energy and a 31% improvement in emotional well-being, resulting in a significant reduction in fatigue.

Why UthPeak® NMNH (Reduced NMN) Stands Apart

Patented Crystalline NMNH (Reduced NMN): The Gold Standard

• First Market-Ready NMNH: UthPeak NMNH (Reduced NMN) offers >98% purity and compatibility with various dosage forms, including powders, tablets, capsules, and more.
• Easier Storage: UthPeak^® NMNH (Reduced NMN)offers superior stability with storage at a convenient 2-8°C, ensuring optimal freshness and efficacy, compared to regular NMNH (Reduced NMN), which requires colder temperatures at -20°C.
• Self-GRAS: UthPeak^® has become the first NMNH brand to secure self-affirmed GRAS status, achieving this milestone for its application in selected conventional foods, dietary supplements, and medical foods.
• Patent Status: Patent pending, crystalline form of NMNH.

From Lab to Life: Real-World Benefits

• Boost In Energy: Enhanced endurance and reduced fatigue, ideal for high-performance lifestyles.
• Cellular Health: Elevated NAD+ supports DNA repair, sirtuin activation, and mitochondrial function, key to slowing age-related decline.

Built for Brands: Safety Meets Scalability

UthPeak® NMNH (Reduced NMN) is a turnkey solution for brands targeting the premium anti-aging market. Clinical validation, Self-GRAS status, and patented technology empower B2B partners to lead in the $30 billion longevity industry.

The Future of Longevity: What’s Next for UthPeak®

EffePharm, creator of the world’s first clinically proven NMN brand, licenses the “Uth” series (UTHEVER^® NMN and UthPeak^® NMNH ) to 50+ global brands.

UthPeak^® NMNH (Reduced NMN) is pioneering next-phase research, including long-term biological age tracking and expanded health markers such as cognitive performance, sleep quality, cardiovascular health, and brain function. Brands are invited to collaborate on NMNH supplement innovations that redefine the concept of aging.

Follow UthPeak® for updates on peer-reviewed publications and upcoming trials. Partner with us to bring science-backed longevity to your customers.